Drug Trial Radar · NCT06253195
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Apr 1, 2024
Primary completion
Apr 23, 2026
Study completion Apr 23, 2026
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, as monotherapy or in combination with fulvestrant, letrozole, or other combination partners in Chinese participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced or metastatic solid tumors.
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Hormone-receptor-positive Breast Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- HER2-negative Breast Cancer
Interventions
BGB-43395Drug
Administered orally.
FulvestrantDrug
Administered via intramuscular injection.
LetrozoleDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 30 months
- Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395Time frame: Up to approximately 30 months
- Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-43395Time frame: Up to approximately 30 months
- Phase 1b: Objective Response Rate (ORR)Time frame: Up to approximately 30 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.